查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1717924

抗体生产市场按产品类型、生产流程、类别、精製方法、应用、最终用户划分－2025-2030 年全球预测

Antibody Production Market by Product, Antibody Type, Production Process, Class, Purification Method, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

抗体生产市场预计到 2024 年将达到 201.6 亿美元，到 2025 年将达到 226.2 亿美元，到 2030 年将达到 407.7 亿美元，复合年增长率为 12.45%。

主要市场统计数据
基准年2024年 201.6亿美元
预计2025年 226.2亿美元
预测年份 2030 407.7亿美元
复合年增长率（%） 12.45%

在不断发展的生物技术领域，抗体生产是一个重要且具变革性的领域。对精确、高品质抗体的需求正在加速生产方法的进步，并激发创新以满足治疗、诊断和研究需求。本摘要对决定当前市场动态的关键市场驱动因素、新兴趋势和策略性细分进行了全面的研究。抗体生产需要对上游工程和下游的细节一丝不苟，以确保每个分子都符合严格的功效和安全标准。多年来，科学创新与技术融合的交叉为生产规模扩大、成本效率和製程优化开闢了新的范式。本入门书专为在快速变化的时代寻求清晰认识的决策者和专业人士而设计，为更深入地讨论市场区隔、区域动态和竞争格局奠定基础。了解抗体製造周围的复杂生态系统可以帮助领导者更好地理解严谨的科学与策略远见的融合，这将推动下一个时代的生物技术进步。

抗体生产格局的变革

在过去的十年中，一场变革重新定义了抗体生产模式。新技术和不断发展的经营模式正在改变传统的生产方式，为更灵活、更有效率的营运铺平道路。生物加工技术和数位创新的进步正在简化工作流程、缩短上市时间并提高产品一致性。上游工程和下游流程中自动化和即时分析的整合不仅提高了产量比率，而且加强了品管措施。这些发展使製造商能够快速回应动态的市场需求和不断变化的法规。随着个人化医疗成为人们关注的焦点，治疗方法方案变得越来越复杂，调整製造流程的能力比以往任何时候都更重要。规模经济和全球合作营造了竞争环境，推动产业领导者不断创新。这一变革时期不仅仅是渐进式的改进，而是向未来的根本转变，速度、适应性和精确度将决定抗体製造的本质。

市场区隔洞察推动市场变革

仔细观察市场区隔可以发现塑造抗体工程生态系的细微驱动因素。从基于产品的细分中获得的见解突出显示了市场如何区分为消耗品、设备和软体。在该领域，消耗品进一步细分为缓衝液和试剂、层析法树脂和介质等子类别，每种消耗品在确保生产过程中的品质和一致性方面都发挥着至关重要的作用。同时，对设备进行了分析，重点关註生物反应器、层析法系统和过滤系统，它们共同支援製造过程的规模和精度。除了物理成分外，抗体依类型划分还可分为单株抗体和多株抗体。製造过程细分将市场划分为下游和上游工程，揭示了影响成本和效率的复杂操作步骤。进一步分类探讨了免疫球蛋白家族，包括 IgA、IgD、IgE、IgG 和 IgM，每种都有独特的结构和功能属性。此外，也研究了精製方法，特别是固定化金属螯合层析法、离子交换层析法和尺寸排除层析法，精製技术直接影响最终产品的纯度和性能。基于应用的细分涵盖诊断、研究和治疗，而在治疗领域内，它探索自体免疫疾病、癌症治疗、感染疾病和神经系统疾病等子领域。最后，按最终用户分析市场可以发现参与企业范围广泛，包括学术和研究机构、生物技术公司、受託研究机构和製药公司。这些细分标准的相互作用不仅阐明了市场的复杂层次，而且还提供了有关成长和差异化机会所在的可行见解。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球消费者慢性病盛行率上升
      • 消费者对标靶治疗和个人化医疗的需求不断增加
      • 医疗基础设施的快速现代化和医疗成本的不断上涨
    • 限制因素
      • 抗体生产研发高成本
    • 机会
      • 双特异性抗体在癌症免疫治疗的新应用
      • 引入新型植物来源抗体的研究活动激增
    • 任务
      • 抗体生产的严格法规结构
  • 市场区隔分析
    • 产品：抗体生产不同阶段耗材的主要用途
    • 应用：随着慢性病变得越来越普遍，抗体生产的治疗用途也不断扩大
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章 抗体生产市场（依产品）

  • 耗材
    • 缓衝液和试剂
    • 层析法树脂
    • 媒体
  • 装置
    • 生物反应器
    • 层析法系统
    • 过滤系统
  • 软体

第七章抗体生产市场（按抗体类型）

  • 单复製
  • 多克隆抗体

第 8 章：抗体生产市场（依生产过程）

  • 下游加工
  • 上游处理

第九章抗体生产市场（按类别）

  • IgA
  • IgD
  • IgE
  • IgG
  • IgM

第十章抗体生产市场（按精製方法）

  • 固定化金属螯合物层析法
  • 离子交换层析法
  • 尺寸排阻层析法

第11章抗体生产市场（依应用）

  • 诊断
  • 调查
  • 治疗
    • 自体免疫疾病
    • 癌症治疗
    • 感染疾病
    • 神经系统疾病

第 12 章抗体生产市场（依最终用户划分）

  • 学术研究所
  • 生技公司
  • 合约研究组织
  • 製药公司

第十三章美洲抗体製造市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

14. 亚太地区抗体製造市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十五章欧洲、中东和非洲抗体製造市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Cell Signaling Technology, Inc.
  • Eppendorf AG
  • F. Hoffmann-La Roche Ltd.
  • Fibercell Systems Inc
  • GE HealthCare Technologies Inc.
  • Genmab A/S
  • GenScript Biotech Corporation
  • Gilead Sciences, Inc.
  • INTEGRA Biosciences AG
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Pall Corporation
  • Pfizer Inc.
  • ProteoGenix
  • Sanofi SA
  • Sartorius AG
  • Teva Pharmaceutical Industries Ltd.
  • The Antibody Company
  • Thermo Fisher Scientific Inc.
Product Code: MRR-69324464D0EA

The Antibody Production Market was valued at USD 20.16 billion in 2024 and is projected to grow to USD 22.62 billion in 2025, with a CAGR of 12.45%, reaching USD 40.77 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 20.16 billion
Estimated Year [2025] USD 22.62 billion
Forecast Year [2030] USD 40.77 billion
CAGR (%) 12.45%

In the ever-evolving landscape of biotechnology, antibody production stands out as both a critical and transformative field. The need for precise, high-quality antibodies has accelerated advancements in production methods, spurring innovations that address therapeutic, diagnostic, and research requirements. This summary offers a comprehensive exploration of the key industry drivers, emerging trends, and strategic segmentation that define current market dynamics. The production of antibodies involves meticulous attention to detail in both upstream and downstream processes, ensuring that each molecule meets stringent efficacy and safety standards. Over the years, the intersection of scientific innovation with technological integration has opened up new paradigms in production scale-up, cost efficiency, and process optimization. This introductory narrative is crafted for decision-makers and experts seeking clarity amid rapid changes, and it lays the groundwork for a deeper discussion on market segmentation, regional dynamics, and competitive landscapes. By understanding the intricate ecosystem surrounding antibody production, leaders can better appreciate the blend of rigorous science and strategic foresight driving the next era of biotechnology advancements.

Transformative Shifts Reshaping the Antibody Production Landscape

Over the past decade, transformative shifts have redefined the antibody production landscape. Emerging technologies and evolving business models have transformed classical production methods, paving the way for more agile and efficient operations. Advances in bioprocessing techniques coupled with digital innovations are streamlining workflows, reducing time-to-market, and enhancing product consistency. The integration of automation and real-time analytics in both upstream and downstream processing has not only improved yield but also enhanced quality control measures. These developments have empowered manufacturers to respond swiftly to dynamic market demands and regulatory changes. As personalized medicine gains prominence and the complexity of therapeutic options increases, the ability to adapt production processes has become more critical than ever. Economies of scale and global collaborations are fostering a competitive environment that pushes industry leaders to innovate continuously. This period of transformation is not merely about incremental improvements; it is a fundamental shift towards a future where speed, adaptability, and precision define the very essence of antibody production.

Key Segmentation Insights Driving Market Nuances

An in-depth examination of market segmentation reveals the nuanced drivers that shape the antibody production ecosystem. Insights drawn from segmentation based on product highlight how the market is differentiated into consumables, instruments, and software. In this arena, consumables are further studied through subcategories such as buffers and reagents, chromatography resins, and media, each playing a crucial role in ensuring quality and consistency during production. Instruments, on the other hand, are analyzed with a focus on bioreactors, chromatography systems, and filtration systems, which collectively support both scale and precision in manufacturing processes. Beyond the physical components, segmentation by antibody type distinguishes between monoclonal and polyclonal antibodies, two critical categories that underscore differences in specificity and application. The production process segmentation, which splits the market between downstream and upstream processing, sheds light on the operational intricacies that influence cost and efficiency. Further division by class explores immunoglobulin families including IgA, IgD, IgE, IgG, and IgM, each with its unique structural and functional attributes. Additionally, purification methods are explored, particularly through techniques like immobilized metal chelate chromatography, ion exchange chromatography, and size exclusion chromatography, which have direct implications on the purity and performance of the final product. Segmentation based on application spans diagnostics, research, and therapeutics, where the therapeutic segment is studied with a lens on subareas such as autoimmune diseases, cancer therapy, infectious diseases, and neurological disorders. Finally, analyzing the market by end-user reveals a broad array of participants ranging from academic and research institutes to biotechnology companies, contract research organizations, and pharmaceutical companies. The interplay of these segmentation criteria not only illuminates the intricate layers of the market but also provides actionable insights into where opportunities for growth and differentiation lie.

Based on Product, market is studied across Consumables, Instruments, and Software. The Consumables is further studied across Buffers & Reagents, Chromatography Resins, and Media. The Instruments is further studied across Bioreactors, Chromatography Systems, and Filtration Systems.

Based on Antibody Type, market is studied across Monoclonal and Polyclonal.

Based on Production Process, market is studied across Downstream Processing and Upstream Processing.

Based on Class, market is studied across IgA, IgD, IgE, IgG, and IgM.

Based on Purification Method, market is studied across Immobilized Metal Chelate Chromatography, Ion Exchange Chromatography, and Size Exclusion Chromatography.

Based on Application, market is studied across Diagnostics, Research, and Therapeutics. The Therapeutics is further studied across Autoimmune Diseases, Cancer Therapy, Infectious Diseases, and Neurological Disorders.

Based on End-User, market is studied across Academic & Research Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies.

Key Regional Insights Shaping Global Dynamics

The global market for antibody production is heavily influenced by regional factors that determine regulatory landscapes, technological adoption rates, and investment priorities. In the Americas, robust infrastructure and high research investments have created an environment where innovation thrives, driven by a strong emphasis on personalized medicine and advanced bioprocess technologies. The Europe, Middle East & Africa region offers a diverse mix of mature markets and emerging economies, where stringent regulatory standards coexist with a resilient focus on quality and sustainability in production practices. Meanwhile, the Asia-Pacific region is rapidly emerging as a powerhouse, propelled by significant investments in biotechnology research and an expanding talent pool. This region is not only scaling up production capacities but also pioneering cost-efficient production methodologies that cater to both local and international markets. The regional disparities and similarities in market dynamics underscore the importance of adopting localized strategies while fostering global best practices. As market players navigate complex regional regulations and cultural idiosyncrasies, these insights provide a roadmap for leveraging regional strengths to build a cohesive, globally competitive strategy.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Leading Innovation and Market Expansion

A review of the competitive landscape reveals a constellation of key players who have been instrumental in driving innovation and setting industry benchmarks. Leading companies such as AbbVie Inc., Amgen Inc., AstraZeneca PLC, and Biogen Inc. have long been recognized for their commitment to research excellence and production efficiency. Similarly, Bristol-Myers Squibb Company, Cell Signaling Technology, Inc., and Eppendorf AG have contributed significantly by integrating next-generation technologies and streamlining manufacturing processes. Influential entities like F. Hoffmann-La Roche Ltd., Fibercell Systems Inc, and GE HealthCare Technologies Inc. continue to push the envelope in quality assurance and product consistency. Further, industry pioneers such as Genmab A/S, GenScript Biotech Corporation, and Gilead Sciences, Inc. exemplify excellence in leveraging cutting-edge biotechnologies, while companies including INTEGRA Biosciences AG, Merck KGaA, and Novartis AG have focused on expanding their global reach and operational capabilities. Equally noteworthy are Novo Nordisk A/S, Pall Corporation, Pfizer Inc., and ProteoGenix, who have diversified their portfolios to address emerging therapeutic needs, along with firms like Sanofi S.A., Sartorius AG, Teva Pharmaceutical Industries Ltd., The Antibody Company, and Thermo Fisher Scientific Inc. which are setting new standards in process optimization and innovation. The strategic initiatives undertaken by these companies collectively shape an industry that is both competitive and collaborative, where continuous innovation remains a hallmark of success.

The report delves into recent significant developments in the Antibody Production Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, Cell Signaling Technology, Inc., Eppendorf AG, F. Hoffmann-La Roche Ltd., Fibercell Systems Inc, GE HealthCare Technologies Inc., Genmab A/S, GenScript Biotech Corporation, Gilead Sciences, Inc., INTEGRA Biosciences AG, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pall Corporation, Pfizer Inc., ProteoGenix, Sanofi S.A., Sartorius AG, Teva Pharmaceutical Industries Ltd., The Antibody Company, and Thermo Fisher Scientific Inc.. Actionable Recommendations for Strategic Industry Leadership

Industry leaders must adopt a forward-thinking approach to harness the evolving opportunities in antibody production. It is imperative to invest in scalable technologies and robust process automation that can reliably enhance production efficiencies and meet diverse clinical needs. Companies are advised to reallocate resources towards research and development, particularly in the realm of purification and process optimization methods, to keep pace with shifting quality standards and regulatory requirements. Aligning strategic initiatives with the insights derived from segmentation and regional trends can unlock new revenue streams and foster sustainable growth. Additionally, fostering partnerships and collaborations with both academic institutions and technology innovators can catalyze the integration of emerging digital tools and bioengineered solutions. A clear focus on risk management and adaptive planning will allow organizations to better mitigate the impact of market volatility and regulatory changes. Ultimately, proactively embracing change and investing in advanced biomanufacturing processes are essential to maintain a competitive edge in a landscape that is increasingly driven by rapid technological progress and global market integration.

Conclusion: Embracing Innovation for Sustainable Growth

The antibody production industry stands at a pivotal moment, characterized by rapid innovation and a heightened demand for precise, efficient manufacturing processes. The analysis presented highlights how a detailed understanding of market segmentation, regional dynamics, and competitive positioning can form the backbone of strategic decision-making. Continuous evolution in production technologies, from innovative consumables and state-of-the-art instruments to advanced purification and process optimization methods, underscores the need for a balanced approach that integrates scientific excellence with operational agility. By embracing these insights and adapting to transformative shifts, industry leaders are well-positioned to drive sustainable growth and maximize value in an increasingly competitive marketplace. As the global economy continues to evolve, companies that invest in research and adapt to emerging trends will not only meet the current demand but also pave the way for future innovations in therapeutic, diagnostic, and research applications.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases among consumers globally
      • 5.1.1.2. Growing demand for targeted therapies and personalized medicines among consumers
      • 5.1.1.3. Rapid modernization of healthcare infrastructure and increase in healthcare expenditure
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with R&D for antibody production
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging applications of bispecific antibodies in cancer immunotherapy
      • 5.1.3.2. Surge in research activities introducing novel plant-made monoclonal antibody
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory frameworks for antibody production
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product : Significant applications of consumables in different stages of antibody production
    • 5.2.2. Application : Expanding usage of antibody production in therapeutics due to the prevalence of chronic diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibody Production Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
    • 6.2.1. Buffers & Reagents
    • 6.2.2. Chromatography Resins
    • 6.2.3. Media
  • 6.3. Instruments
    • 6.3.1. Bioreactors
    • 6.3.2. Chromatography Systems
    • 6.3.3. Filtration Systems
  • 6.4. Software

7. Antibody Production Market, by Antibody Type

  • 7.1. Introduction
  • 7.2. Monoclonal
  • 7.3. Polyclonal

8. Antibody Production Market, by Production Process

  • 8.1. Introduction
  • 8.2. Downstream Processing
  • 8.3. Upstream Processing

9. Antibody Production Market, by Class

  • 9.1. Introduction
  • 9.2. IgA
  • 9.3. IgD
  • 9.4. IgE
  • 9.5. IgG
  • 9.6. IgM

10. Antibody Production Market, by Purification Method

  • 10.1. Introduction
  • 10.2. Immobilized Metal Chelate Chromatography
  • 10.3. Ion Exchange Chromatography
  • 10.4. Size Exclusion Chromatography

11. Antibody Production Market, by Application

  • 11.1. Introduction
  • 11.2. Diagnostics
  • 11.3. Research
  • 11.4. Therapeutics
    • 11.4.1. Autoimmune Diseases
    • 11.4.2. Cancer Therapy
    • 11.4.3. Infectious Diseases
    • 11.4.4. Neurological Disorders

12. Antibody Production Market, by End-User

  • 12.1. Introduction
  • 12.2. Academic & Research Institutes
  • 12.3. Biotechnology Companies
  • 12.4. Contract Research Organizations
  • 12.5. Pharmaceutical Companies

13. Americas Antibody Production Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Antibody Production Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Antibody Production Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Sanofi invests EUR 40 million to elevate antibody production at Lyon site
    • 16.3.2. AtomVie and Radiopharm Ventures team up to develop and manufacture monoclonal antibody 177Lu-BetaBart
    • 16.3.3. GigaGen's contract with US BARDA accelerates recombinant polyclonal antibodies for BoNT and biothreats
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Biogen Inc.
  • 5. Bristol-Myers Squibb Company
  • 6. Cell Signaling Technology, Inc.
  • 7. Eppendorf AG
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. Fibercell Systems Inc
  • 10. GE HealthCare Technologies Inc.
  • 11. Genmab A/S
  • 12. GenScript Biotech Corporation
  • 13. Gilead Sciences, Inc.
  • 14. INTEGRA Biosciences AG
  • 15. Merck KGaA
  • 16. Novartis AG
  • 17. Novo Nordisk A/S
  • 18. Pall Corporation
  • 19. Pfizer Inc.
  • 20. ProteoGenix
  • 21. Sanofi S.A.
  • 22. Sartorius AG
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. The Antibody Company
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. ANTIBODY PRODUCTION MARKET MULTI-CURRENCY
  • FIGURE 2. ANTIBODY PRODUCTION MARKET MULTI-LANGUAGE
  • FIGURE 3. ANTIBODY PRODUCTION MARKET RESEARCH PROCESS
  • FIGURE 4. ANTIBODY PRODUCTION MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 21. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 25. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 30. ANTIBODY PRODUCTION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 31. ANTIBODY PRODUCTION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIBODY PRODUCTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY PRODUCTION MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY BUFFERS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CHROMATOGRAPHY RESINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY POLYCLONAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY IGA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY IGD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY IGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY IGG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY IGM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY IMMOBILIZED METAL CHELATE CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CANCER THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 292. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 300. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 302. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 310. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 311. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 312. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 314. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 320. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 321. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 322. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 324. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 330. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 332. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 333. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 334. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 335. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 336. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 337. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 338. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 340. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 341. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 342. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 343. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 344. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 345. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 346. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 347. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
  • TABLE 348. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018